Prevention of glucocorticoid-induced osteoporosis with alendronate or alfacalcidol: Relation between change in bone mineral density, bone markers and calcium homeostasis.

被引：0
|
作者：
Jacobs, JWG
de Nijs, RNJ
Lems, WF
Geusens, PP
Huisman, MAM
Laan, RFJ
Bijlsma, JWJ
机构：
[1] Univ Utrecht, Med Ctr, Utrecht, Netherlands
[2] Free Univ Amsterdam Hosp, Amsterdam, Netherlands
[3] State Univ Limburg Hosp, NL-6201 BX Maastricht, Netherlands
[4] Sint Franciscus Hosp, Rotterdam, Netherlands
[5] Univ Med Ctr, Nijmegen, Netherlands
来源：
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S295 / S295
页数：1
相关论文
共 50 条
  • [21] Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk
    Kenanidis, Eustathios
    Potoupnis, Michael E.
    Kakoulidis, Panagiotis
    Leonidou, Andreas
    Sakellariou, Grigorios T.
    Sayegh, Fares E.
    Tsiridis, Eleftherios
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (07) : 1035 - 1053
  • [22] The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis
    Kaji, H
    Yamauchi, M
    Chihara, K
    Sugimoto, T
    ENDOCRINE JOURNAL, 2006, 53 (01) : 27 - 34
  • [23] Clinical significance of bone markers in glucocorticoid-induced osteoporosis (GIO).
    Tanaka, I.
    Oshima, H.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S236 - S236
  • [24] Prevention of glucocorticoid-induced osteoporosis: A randomized clinical trial with alendronate versus alfacalcidol. The Stop-Study
    de Nijs, R
    Jacobs, J
    Buskens, E
    Huisman, A
    Algra, A
    Laan, R
    de Laet, C
    Lems, W
    Bijlsma, J
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 94 - 94
  • [25] Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis
    Mengu Sarioglu
    Cigdem Tuzun
    Zeliha Unlu
    Canan Tikiz
    Fatma Taneli
    B. Sami. Uyanik
    Rheumatology International, 2006, 26 : 195 - 200
  • [26] Effects of raloxifene and alendronate on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis
    Johnell, O
    Lu, Y
    Seeman, E
    Reginster, J
    Scheele, W
    OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S184 - S184
  • [27] Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis
    Sarioglu, M
    Tuzun, C
    Unlu, Z
    Tikiz, C
    Taneli, F
    Uyanik, BS
    RHEUMATOLOGY INTERNATIONAL, 2006, 26 (03) : 195 - 200
  • [28] Alendronate increased bone mineral density but did not reduce new fractures in glucocorticoid induced osteoporosis - Commentary
    Compston, JE
    GUT, 1999, 44 (06) : 780 - 781
  • [29] The effects of alendronate treatment on vertebral mineral density and bone turnover in 16 women with glucocorticoid induced osteoporosis
    Dumitrache, C
    Grigorie, D
    Barbu, C
    Neacsu, E
    Dumitrache, M
    Grigorie, M
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S46 - S47
  • [30] The relation between dietary calcium intake and bone mineral density in postmenopausal osteoporosis
    Cerrahoglu, L
    Duruöz, MT
    Tikiz, C
    Olcenler, S
    Tulukoglu, N
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S89 - S89
12345